Literature DB >> 34071777

Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways.

Enxhi Shaba1, Claudia Landi2, Alfonso Carleo3, Lorenza Vantaggiato2, Eugenio Paccagnini4, Mariangela Gentile4, Laura Bianchi2, Pietro Lupetti4, Elena Bargagli5, Antje Prasse3, Luca Bini2.   

Abstract

In the longtime challenge of identifying specific, easily detectable and reliable biomarkers of IPF, BALF proteomics is providing interesting new insights into its pathogenesis. To the best of our knowledge, the present study is the first shotgun proteomic investigation of EVs isolated from BALF of IPF patients. Our main aim was to characterize the proteome of the vesicular component of BALF and to explore its individual impact on the pathogenesis of IPF. To this purpose, ultracentrifugation was chosen as the EVs isolation technique, and their purification was assessed by TEM, 2DE and LC-MS/MS. Our 2DE data and scatter plots showed considerable differences between the proteome of EVs and that of whole BALF and of its fluid component. Analysis of protein content and protein functions evidenced that EV proteins are predominantly involved in cytoskeleton remodeling, adenosine signaling, adrenergic signaling, C-peptide signaling and lipid metabolism. Our findings may suggest a wider system involvement in the disease pathogenesis and support the importance of pre-fractioning of complex samples, such as BALF, in order to let low-abundant proteins-mediated pathways emerge.

Entities:  

Keywords:  BALF; EVs; IPF; shotgun proteomics

Year:  2021        PMID: 34071777     DOI: 10.3390/ijms22115696

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  53 in total

1.  HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis.

Authors:  Kemly Philip; Tingting Weng Mills; Jonathan Davies; Ning-Yuan Chen; Harry Karmouty-Quintana; Fayong Luo; Jose G Molina; Javier Amione-Guerra; Neeraj Sinha; Ashrith Guha; Holger K Eltzschig; Michael R Blackburn
Journal:  FASEB J       Date:  2017-07-12       Impact factor: 5.191

Review 2.  Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis.

Authors:  Paolo Cameli; Alfonso Carleo; Laura Bergantini; Claudia Landi; Antje Prasse; Elena Bargagli
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

Review 3.  Molecular networks underlying myofibroblast fate and fibrosis.

Authors:  April Stempien-Otero; Deok-Ho Kim; Jennifer Davis
Journal:  J Mol Cell Cardiol       Date:  2016-05-07       Impact factor: 5.000

4.  S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.

Authors:  Atsuko Hara; Noriho Sakamoto; Yuji Ishimatsu; Tomoyuki Kakugawa; Shota Nakashima; Shintaro Hara; Misato Adachi; Hanako Fujita; Hiroshi Mukae; Shigeru Kohno
Journal:  Respir Med       Date:  2011-12-30       Impact factor: 3.415

Review 5.  Targeting metabolic dysregulation for fibrosis therapy.

Authors:  Xiao Zhao; Jennifer Yin Yee Kwan; Kenneth Yip; Peter P Liu; Fei-Fei Liu
Journal:  Nat Rev Drug Discov       Date:  2019-09-23       Impact factor: 84.694

6.  Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases.

Authors:  E Bargagli; C Olivieri; A Prasse; N Bianchi; B Magi; R Cianti; L Bini; P Rottoli
Journal:  Inflammation       Date:  2008-10       Impact factor: 4.092

7.  SWATH label-free proteomics for cystic fibrosis research.

Authors:  Clarissa Braccia; Valeria Tomati; Emanuela Caci; Nicoletta Pedemonte; Andrea Armirotti
Journal:  J Cyst Fibros       Date:  2018-10-19       Impact factor: 5.482

8.  Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis.

Authors:  E Bargagli; C Olivieri; N Nikiforakis; M Cintorino; B Magi; M G Perari; C Vagaggini; D Spina; A Prasse; P Rottoli
Journal:  Respir Physiol Neurobiol       Date:  2009-05-21       Impact factor: 1.931

9.  Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice.

Authors:  Carolina Costola-de-Souza; Alison Ribeiro; Viviane Ferraz-de-Paula; Atilio Sersun Calefi; Thiago Pinheiro Arrais Aloia; João Antonio Gimenes-Júnior; Vinicius Izidio de Almeida; Milena Lobão Pinheiro; João Palermo-Neto
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

10.  Common molecular pathways targeted by nintedanib in cancer and IPF: A bioinformatic study.

Authors:  Landi C; Carleo A; Vantaggiato L; Bergantini L; Cameli P; Sebastiani G; Dotta F; Bargagli E
Journal:  Pulm Pharmacol Ther       Date:  2020-09-05       Impact factor: 3.410

View more
  4 in total

Review 1.  Recent Advances in Molecular Diagnosis of Pulmonary Fibrosis for Precision Medicine.

Authors:  Mi Ho Jeong; Hongwei Han; David Lagares; Hyungsoon Im
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-20

Review 2.  Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone.

Authors:  Enxhi Shaba; Lorenza Vantaggiato; Laura Governini; Alesandro Haxhiu; Guido Sebastiani; Daniela Fignani; Giuseppina Emanuela Grieco; Laura Bergantini; Luca Bini; Claudia Landi
Journal:  Proteomes       Date:  2022-04-22

Review 3.  Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis.

Authors:  Olivier Burgy; Sabrina Loriod; Guillaume Beltramo; Philippe Bonniaud
Journal:  Cells       Date:  2022-04-03       Impact factor: 6.600

Review 4.  Current and prospective applications of exosomal microRNAs in pulmonary fibrosis (Review).

Authors:  Tao Yang; Jian Wang; Jiaying Zhao; Yang Liu
Journal:  Int J Mol Med       Date:  2022-01-28       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.